Clinical Trial Update: Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating transcatheter arterial chemoembolization combined with sorafenib in unresectable hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma, Face Cancer | Phase 3 | Status: COMPLETED